{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-283667","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.132782+00:00","generated_at":"2026-06-21T20:54:58.654879+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cullinan Oncology reports Q3 net loss $24.9M; initiates pivotal zipalertinib study","bullets":["Initiated pivotal study for zipalertinib in EGFR exon 20 NSCLC; cohort to evaluate 150 mg BID with food.","Increased ownership in MICA (CLN-619) from 54% to 92% for $30.7M cash.","Cash and investments $606.7M at Sept 30, 2022; runway extends beyond key milestones.","Net loss before noncontrolling interest $24.9M; R&D expenses $19.7M, G&A $10.1M.","Appointed Jacquelyn Sumer as CLO and Dr. David Ryan to Board; IND filings for CLN-617, CLN-978 on track for H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-283667","json":"https://secwatch.observer/filing/0001193125-22-283667.json","markdown":"https://secwatch.observer/filing/0001193125-22-283667.md","text":"https://secwatch.observer/filing/0001193125-22-283667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/0001193125-22-283667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/d371812d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:54:58.654879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a0da73026163cd35b1a608d8d74063b23505dbe","claim":"Cullinan Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/0001193125-22-283667-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}